Might tocilizumab be useful in patients with giant-cell arteritis and normal ESR?
نویسندگان
چکیده
We read with great interest the original article “Rapid induction of remission in large vessel vasculitis by IL-6 blockade” by Dr. Seitz et al. [1]. One of us (F.J.F-F) is very interested in the treatment of giant-cell arteritis because his mother was diagnosed with giant-cell arteritis 5 months previously. She had polymyalgia rheumatic for several months, and headache was the main manifestation of her arteritis. She is 82 years-old and has hypertension and diabetes mellitus. She did not have anaemia or constitutional symptoms. C-reactive protein and erythrocyte sedimentation rate (ESR) were low when she was diagnosed with giant cell arteritis (5.4 mg/L and 34 mm/h, respectively). The values of these parameters were normal when she was diagnosed with polymyalgia rheumatica. One week after treatment with 60 mg/day of prednisone, which was the used dose for the initial management of her arteritis, her serum levels of IL-6 and C-reactive protein were 2.8 pg/ml and 0.31 mg/L, respectively. During a relapse, 3 months after the diagnosis of giant-cell arteritis, IL-6, C-reactive protein and ESR were elevated to 5.8 pg/ml, 8.1 mg/L and 26 mm/ h, respectively. Her treatment with prednisone is accompanied by a notable worsening of her diabetes requiring treatment with insulin. Furthermore, central nervous system manifestations with insomnia and irritability were remarkable. In other recent case reports, tocilizumab has been used successfully in patients with giant-cell arteritis and elevated acute phase reactants [2–3]. Theoretically, one might think that tocilizumab would not be useful in patients with giantcell arteritis and a weak inflammatory response. The article by Dr. Seitz and colleagues is interesting in several respects. On the one hand, in two of their patients monotherapy with tocilizumab only was used to induce remission. On the other hand, one of their patients had normal ESR and C-reactive protein. We would like to know whether Seitz and colleagues measured the serum levels of IL-6 before and after treatment with tocilizumab. Particularly, it would be interesting to know whether their patient with normal ESR had normal values of IL-6 before treatment with tocilizumab. Perhaps, tocilizumab may be the steroidsparing agent that we are expecting if the results of Seitz and colleagues are confirmed by larger series of patients.
منابع مشابه
Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
The erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were measured in 74 patients with polymyalgia rheumatica (PMR)/giant cell arteritis (GCA) on presentation, in the first month of treatment, and at long term follow up (up to 177 weeks). Before treatment the ESR was raised (greater than 30 mm/h) in all cases and the CRP was raised (greater than 6 mg/l) in 49/55 cases. The ESR ...
متن کاملSuccessful Treatment of Giant Cell Arteritis with Tocilizumab: Report of 2 Cases with Review of the Literature
Giant cell arteritis (GCA) is a systemic vasculitis of medium and large vessels. Corticotherapy is the cornerstone treatment, but most patients fail to reach remission or relapse during the weaning of Glucocorticoids (GC). Here we report 2 patients with corticoid dependent GCA, successfully treated with Tocilizumab (TCZ), with a rapid clinical and biological outcome allowing the tapering of GC,...
متن کاملHistopathologic Features of Giant Cell Arteritis in an Actinic Granuloma Lesion
The association between actinic granuloma and giant cell arteritis (temporal arteritis) has been claimed by some authors. There is a hypothesis that actinic radiation has the principal role in the etiology of both diseases in a similar way. Here, we report a case of actinic granuloma that had characteristic pathologic features of giant cell arteritis in histopathologic examination without clini...
متن کاملGiant cell arteritis: diagnosis and management.
Giant cell arteritis should not be a diagnosis of exclusion, an afterthought, or a last thought. There is urgency to establishing this diagnosis and initiating therapy. All practitioners who treat adults will be confronted with these patients. Some will have classic presentations, some will have subtle presentations. When patients complain of fever, fatigue, malaise, weight loss, or painless vi...
متن کاملPlasma viscosity in giant cell arteritis as a predictor of disease activity.
Thirty one patients with giant cell arteritis (GCA) receiving standardised prednisolone treatment were followed up for one year with analyses of plasma viscosity, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and fibrinogen concentration. On the day of diagnosis all patients had an increased plasma viscosity and ESR, whereas the concentration of CRP was normal in three patient...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Swiss medical weekly
دوره 142 شماره
صفحات -
تاریخ انتشار 2012